Overexpression of SMPDL-3b or treatment with rituximab of a human podocyte cell culture could prevent podocyte apoptosis or disruption of the actin cytoskeleton induced by sera of patients with recurrent FSGS after kidney transplantation. Here, SMPDL3B is linked to focal segmental glomerulosclerosis.